Free Trial

Cel-Sci (CVM) FDA Approvals

Cel-Sci logo
$1.28 +0.09 (+7.56%)
Closing price 11/13/2026 04:10 PM Eastern
Extended Trading
$1.27 -0.01 (-0.78%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cel-Sci's Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Cel-Sci (CVM). Over the past two years, Cel-Sci has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Multikine. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Multikine FDA Regulatory Events

Multikine is a drug developed by Cel-Sci for the following indication: Head and Neck Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Cel-Sci FDA Events - Frequently Asked Questions

As of now, Cel-Sci (CVM) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Cel-Sci (CVM) has reported FDA regulatory activity for Multikine.

The most recent FDA-related event for Cel-Sci occurred on October 26, 2026, involving Multikine. The update was categorized as "Provided Update," with the company reporting: "CEL-SCI Corporation announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*."

Currently, Cel-Sci has one therapy (Multikine) targeting the following condition: Head and Neck Cancer.

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NYSEAMERICAN:CVM last updated on 10/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners